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There is substantial evidence that age-related ovarian failure in rats is preceded by abnormal
responsiveness of the neuroendocrine axis to estrogen positive feedback. Because IGF-I seems to
act as a permissive factor for proper GnRH neuronal response to estrogen positive feedback and
considering that the hypothalamic content of IGF-I declines inmiddle-aged (M-A) rats, we assessed
the effectiveness of long-term IGF-I gene therapy in the mediobasal hypothalamus (MBH) of M-A
female rats toextend regular cyclicity andpreserveovarian structure.Weused3groupsofM-Arats:
1 group of intact animals and 2 groups injected, at 36.2 weeks of age, in the MBH with either a
bicistronic recombinant adeno-associated virus (rAAV) harboring the genes for IGF-I and the red
fluorescent protein DsRed2, or a control rAAV expressing only DsRed2. Daily vaginal smears were
taken throughout the study, which ended at 49.5 weeks of age. We measured serum levels of
reproductive hormones and assessed ovarian histology at the end of the study. Although most of
the rats injected with the IGF-I rAAV had, on the average, well-preserved estrous cyclicity as well
as a generally normal ovarian histology, the intact and control rAAV groups showed a high per-
centage of acyclic rats at the end of the study and ovaries with numerous enlarged cysts and scarce
corpora lutea. Serum LH was higher and hyperprolactinemia lower in the treated animals. These
results suggest that overexpression of IGF-I in the MBH prolongs normal ovarian function in M-A
female rats. (Endocrinology 154: 2166–2173, 2013)
There is substantial evidence that age-related ovarianfailure in rats is preceded by abnormal responsiveness
of the neuroendocrine system to estrogen positive feed-
back. Thus, middle-aged (M-A), eugonadal rats demon-
strate increased FSH serum levels as well as delayed and
attenuated LH surges despite normal estrous (E) cycle
lengths (1). Changes in the positive feedback effects of
estradiol on theLHsurge in regularly cycling,M-Arats are
not due to primary pituitary dysfunction (2, 3), or reduced
estrogen receptor a or progestin receptor expression
and/or binding in the hypothalamus (4–6) or the pituitary
(7, 8). Instead, available data overwhelmingly point to an
impaired hypothalamic response to estradiol positive, but
not negative (9, 10), feedback as the etiology of the alter-
ations in LH release typically observed in reproductively
aging rodents (11). At the hypothalamic level, the age-
related dysfunction of the LH surge is attributable neither
to reduced numbers or abnormal morphology of GnRH
neurons (12–15) nor to reduced GnRH peptide content,
which remains unchanged or even increases with age (3).
On the other hand, push-pull perfusion measurements of
in vivo GnRH output from the mediobasal hypothalamus
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(MBH) of M-A rats suggest that GnRH peptide release is
attenuated under estradiol positive feedback conditions
(16). Moreover, GnRH mRNA may decrease (17), and
fewer GnRH neurons express cFos (12, 18), a marker for
GnRH neuron activation, in M-A compared with young
rats (12, 18). Taken together, the available data suggest
that decreased preovulatory GnRH release most likely re-
flects impairedGnRHneuronal activation under estrogen
positive feedback conditions (19). There is solid evidence
that M-A rats do not respond to estradiol positive feed-
back with appropriate modulation of excitatory and in-
hibitory hypothalamic neurotransmitter release (2, 18,
20–23), which in turn could cause reduced activation of
GnRH neurons, reduced GnRH release, and an abnormal
LH surge (18, 23). The initial deterioration of the modu-
lation of excitatory and inhibitory hypothalamic neu-
rotransmitter release inM-A female rats may stem from a
reduction in the activity of permissive factors like IGF-I,
whose content is reduced in the brains of M-A rats (17).
Interestingly, it has been reported that intracerebroven-
tricular infusion of IGF-I partially rescues the LH surge in
M-A rats (3). IGF-I signaling, presumably in the hypo-
thalamus, is necessary for estradiol positive feedback and
may modulate the synthesis or release of kisspeptin or
vasointestinal peptide and/or the expression of glutamate
receptors (24, 25). Thus, it is possible that reduced hypo-
thalamic IGF-I indirectly affects GnRHneuron activity by
disrupting excitatory inputs mediated by glutamate and
kisspeptin (26–28).
Besides its permissive role in themodulationof theGnRH
system, IGF-I is known to be a powerful neurotrophic mol-
ecule, which appears to be part of the physiologic self-repair
mechanisms of the adult brain (29). Furthermore, gene ther-
apy for IGF-I has shown promising results in the brain of
aging rats. Thus, IGF-I gene therapy in the MBH of senile
female rats was highly effective to restore hypothalamic do-
paminergic neuron number and correct the chronic hyperp-
rolactinemia associated with depressed tuberoinfundibular
dopaminergic neuron function in old female rats (30). In the
sameanimalmodel, intracerebroventricular IGF-I gene ther-
apyameliorated the reducedmotorperformanceof the senile
animals (31, 32).
In the present study, we assessed the effectiveness of
long-term IGF-I gene therapy in theMBH of cycling adult
female rats to extend regular cyclicity and preserve ovar-
ian structure when the animals progress through M-A.
Materials and Methods
Adeno-associated virus (AAV) vectors.
The recombinant AAV (rAAV) shuttle plasmids, pAAV-cy-
tomegalovirus (CMV)-IGF-1b-internal ribosome entry site
(ires)-Discosoma red fluorescent protein (DsRed) and pAAV-
CMV-ires-DsRed, were made by cloning an expression cassette
between the 2 inverted terminal repeats of anAAV2 shuttle plas-
mid using standard techniques. Both plasmids contain an ex-
pression cassette driven by a CMVpromoter containing a b-glo-
bin intron enhancer. The 934-bp rat IGF-Ib sequence was
obtained from Peter Rotwein (Oregon Health Sciences Univer-
sity). Both plasmids also contain an ires upstream of the cellular
reporter gene DsRed2. The expression cassettes were confirmed
by DNA sequencing and expression of DsRed2 in transfected
HeLa cells before preparing high titer, helper-free rAAV. Both
vectors were packaged as rAAV2/2 by the Children’s Memorial
ViralVectorCore following the protocol ofZolotukhin et al (33)
with minor modifications. In brief, a shuttle plasmid and the
pDG packaging plasmid (generously provided by Jürgen Klein-
schmidt) (34) were used at a ratio of 1:3, respectively, for CaCl2
transfection into 293T cells. Cells were lysed 3 days after trans-
fection by freeze-thawing in order to collect virus, and cellular
debris was removed by centrifugation. The supernatant was
treatedwith octyl-b-D-glucopyranoside andbenzonase and then
applied to a 15%–60% iodixanol discontinuous gradient. The
40% layer was further purified using aMustangQ ion exchange
membrane. A Centriplus 100,000 MS cut off membrane was
used to concentrate virus, which was stored in PBS (pH 7.4),
containing 5% sorbitol and 0.001% Pluronic F68. Quantitative
RT-PCR was used to determine viral titers. Viral titers were:
rAAV-IGF-I-ires-DsRed, 2.0 3 1012 vector genomes (vg)/mL;
rAAV-ires-DsRed, 3.9 3 1012 vg/mL.
In vitro studies
Cell cultures
TheHEK293 human embryo kidney cell line was used to test
the performance of rAAV-IGF-I-ires-DsRed in vitro. Cells were
grown in Eagle’s MEM, 16.8mMHEPES buffer (pH 7.0), 2mM
glutamine, 0.1mMnonessential aminoacids, 20-mg/Lpenicillin/
streptomycin, 3.3-mg/L amphotericin B, 2.2-mg/L NaHCO3,
and 10% (vol/vol) fetal bovine serum. They were grown at 37°C
in a humidified atmosphere of 95% air-5% CO2. Cells were fed
every 3-4 days and split when confluent.
Cell transduction protocol
Cells were plated on 12-well plates. When 70%–80% con-
fluence was reached, the medium was replaced with fresh me-
dium containing 4.8 3 109 vg/mL rAAV-IGF-I-ires-DsRed or
2.5 3 109 vg/mL rAAV-ires-DsRed. At appropriate times, cell
supernatants were collected by gentle aspiration, 1-mL 0.1%
Triton X-100 in PBS per well was added to cells, and they were
scrapped off. Cell suspensions were freeze-thawed 3 times, cen-
trifuged at 1000g for 10 minutes, and lysates collected for flu-
orescencedeterminationby spectrofluorometry.Total IGF-Iwas
measured in supernatants.
Animals and in vivo procedures
Female Sprague-Dawley rats aged 3, 8, 10, and 26 months
were used. The animals were raised in our institution (Instituto
de Investigaciones Bioquímicas de La Plata) and housed in a
temperature-controlled room (22 6 2°C) on a 12-hour light,
12-hour dark cycle (lights on from7 AM to 7 PM). Food andwater
were available ad libitum. All experiments with animals were
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performed according to the Animal Welfare Guidelines of Na-
tional Institutes of Health (Instituto de Investigaciones Bio-
químicas de La Plata’s Animal Welfare Assurance A5647-01).
Stereotaxic injections
Rats were anesthetized with ketamine hydrochloride (40mg/
kg; ip) plus xylazine (8 mg/kg; im) and placed on a stereotaxic
apparatus. In order to access the MBH, the tip of a 26-G needle
fitted to a 10-mL syringe was brought to the following coordi-
nates relative to the bregma: 3.0 mm posterior, 8.0 mm ventral,
and 0.6 mm right and left (35).
Vaginal smears
Vaginal secretion was collected daily, between 11 AM and 1
PM, with a plastic pipette filled with 20-mL normal saline (NaCl
0.9%) by inserting the tip into the rat vagina but not deeply. A
drop of vaginal fluid was smeared on a glass slide, and the un-
stained material was observed under a light microscope, with a
403 phase-contrast objective. Three types of cells can be recog-
nized: round and nucleated ones are epithelial cells, irregular
oneswithout nucleus are cornified cells, and little round ones are
leukocytes. The proportion among them was used for determi-
nation of the E cycle phases (36, 37), which are indicated as
follows, proestrus (P), E, metestrus, diestrus (D), P entering E,
and D entering P.
InM-A rats spending several days in a row in constant E (CE),
a CE cycle was defined, for quantitation purposes, as a period of
5 consecutive days of vaginal smears showing only cornified
cells. For instance, if an animal spent 13 days in a row inCE, they
were counted as 13/5 5 2.6 CE cycles.
Experimental design for long-term IGF-I gene
therapy in cycling females
Eight-month-old (34 wk) cycling females were allotted to a
control or experimental group, thus forming 3 groups: intact
control (intact), rAAV-DsRed-injected control (DsRed), and
rAAV-IGF-I-ires-DsRed-injected experimental (IGF-I). Begin-
ning at age 35.5 weeks, a small blood sample (0.3–0.4 mL) was
taken (between 11 AM and 1 PM) from the tail veins of all rats at
appropriate intervals throughout the experiment. Serumwas ob-
tained and kept at 220°C for hormone assay. Vaginal smears
were assessed daily from the beginning to the end of the study. At
36.2weeks of age, theDsRed and IGF-I groups received bilateral
2.0-mL intrahypothalamic (MBH) injections containing 43 109
vg rAAV-DsRed or rAAV-IGF-I-ires-DsRed, respectively. The
experimentwas endedwhen the animals reachedage49.5weeks.
Brain processing for fluorescence microscopy
Five DsRed and 5 IGF-I animals were placed under deep an-
esthesia and perfused with phosphate-buffered formaldehyde
4% (pH 7.4) fixative. Each brain was removed and serially cut
into coronal sections 40mm thick on a vibratome. Sections were
placedon regular slides,mountedwithFluoromountG (Electron
Microscopy Sciences, Hatfield, Pennsylvania), and observed un-
der an Olympus BX51 fluorescence microscope (Olympus, To-
kyo, Japan). Digital images were captured with an Olympus
DP70 digital camera.
Histologic and histomorphometric assessment of
ovaries
Ovaries were removed, fixed in 4% formaldehyde, dehy-
drated, and embedded in paraffin. Four-micrometer-thick serial
sections, cut following the organ’s major axis, were stained with
hematoxylin and eosin. Micrographs of ovarian sections were
taken with a digital camera CanonMC30 attached to an Olym-
pus CX31 microscope. The number of mature and developing
follicles, corpora lutea (CL), and cysts per ovarian section was
determined using 6 images per gonad (which were at least 100
mm apart) taken with a 43 objective. The assessment of the
ovaries was done by 2 blind observers (C.G.B. andM.A.F.). The
criteria for histologically grading the ovaries were based on pre-
vious studies in young rats (38, 39) and adapted for the ovarian
features of M-A rats. The grades are as follows:
Grade 1, corresponds to ovaries with an average of 1 ormore
large cysts, less than 1 CL and less than 1 mature or growing
follicle per section;
Grade 2, corresponds to ovaries showing small or medium-
sized but not large cysts, between 1 and less than 2.5 CL and
between 1 and 1.5 mature or growing follicles per section;
Grade 3, corresponds to ovaries without medium-sized or
large cysts andwith an average of 2.5 ormoreCL aswell asmore
than 1.5 mature or growing follicles.
Hormone assays
IGF-I assay
IGF-I was extracted from serum by acid-ethanol cryoprecip-
itation and was radioimmunoassayed (RIA) as previously de-
scribed (30) using antibody UB2-495 distributed by Dr A. F.
Parlow (Pituitary Hormones and Antisera Center, Harbor-Uni-
versity of California, Los Angeles (UCLA)Medical Center, Tor-
rance, California). Recombinant human IGF-I (Cell Sciences,
Inc, Canton, Massachusetts) was used as tracer and unlabeled
ligand. Cell supernatants were homogenized in PBS, and IGF-I
was extracted by acid-ethanol cryoprecipitation and quantified
by RIA. The sensitivity and intraassay coefficient of variation
(CV) for IGF-I was 2.4 ng/mL and 11%, respectively.
Pituitary hormone assays
Serumprolactin (PRL)andLHweremeasuredby specificRIA
using the rat materials provided by Dr A. F. Parlow. Serum PRL
and LH were expressed in terms of National Hormone and Pi-
tuitary Program rat prolactin reference preparation 3, and rat
luteinizing hormone reference preparation 3, respectively. The
sensitivity and intraassay CV for LH and PRL was 0.6 ng/mL,
14% and 2.3 ng/mL, 13%, respectively.
Steroid hormone assays
Serum progesterone (P4) levels were measured by solid phase
RIA using a commercial kit (Coat-A-Count, DPC; Diagnostic
Products Corp, Los Angeles, California). Serum b-estradiol (E2)
wasmeasuredusing a liquidphase commercialRIAkit (Estradiol
Ultrasensitive DSL 4800; Diagnostic Systems Laboratories,
Webster, Texas). The sensitivity and intrassay CV for E2 and P4
were 4.1 pg/mL, 8% and 27 ng/mL, 5%, respectively.
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Statistical analysis
Data are expressed as mean 6 SEM, unless otherwise indi-
cated. Formultiple experimental groups, statistical comparisons
were performed by 1-way ANOVA followed by the Tukey pos
hoc test when the ANOVA was significant. For comparisons
betweenpairsofmeans theStudent’s t testwasusedwhen theSDs
did not differ significantly. Otherwise, theWelch’s approximate
t estimator was used.
Results
Characterization of E cyclicity of female rats at
different ages
E cycle patterns throughout the lifespan
Preliminary characterization inour female rat colonyofE
cycle patterns from youth through very old age showed that
transition from regular to irregular cyclicity takes place at
around9monthsofageandis followedbyaprevalenceofCE
status from age 10 to 18-20 months. Thus, 3-month-old fe-
males typically show 4- to 5-day E cycles characterized by 1
day or less of P (in some cycles, P was so short that when
vaginal smear was performed the cell proportion was con-
sistentwithP enteringEor sometimes just E), 1dayofE, and
2-3 days of metestrus and/or D (data not shown). Ten-
month-old females typically showaprevalenceof lengthyCE
periods with interspersed irregular cycles (data not shown).
In vitro DsRed and IGF-I gene transfer
Both rAAV-DsRed and rAAV-IGF-I-ires-DsRed induced
strong red fluorescence in HEK293 cell cultures (data not
shown). rAAV-IGF-I-ires-DsRed showed a strong overex-
pression of IGF-I when compared with nontreated cells or
cells incubated with rAAV-DsRed (Supplemental Figure 1,
graph,publishedonTheEndocrineSociety’sJournalsOnline
web site at http://endo.endojournals.org). IGF-I concentra-
tioninthesupernatantspeakedonday2aftervectoraddition
and remained steady afterwards. No cytopathic effect was
detected in either control or experimental cells at the vector
concentrations used.
IGF-I gene therapy in the MBH
Expression of transgenic DsRed in the MBH
Both rAAV-DsRed and rAAV-IGF-I-ires-DsRed induced
strong red fluorescence in the MBH of M-A females from
postvector injection day 3 until the end of the treatment at
postvector injectionday93 (Supplemental Figure1, images).
As expected, most of the transduced cells were neurons and
in most of the animals were distributed radiating from the
needle track within the MBH. Vector diffusion did not ex-
tend beyond this region. Visual comparison of DsRed ex-
pression in different animals revealed some interanimal vari-
ability concerning the locationwhere the vectorwas injected
within theMBH, but around each needle track, the number
of fluorescent neurons appeared comparable between sides
and among animals.
Effect of long-term hypothalamic IGF-I gene
therapy on E cycles in M-A rats
Injection of rAAV-IGF-I-ires-DsRed in the MBH of
36.2-week-old femaleshada favorable impact,whencom-
Figure 1. Effect of long-term MBH IGF-I gene therapy on the
frequency of regular, irregular, and CE cycles in M-A female rats. Rats
had their vaginal cytology assessed daily from 34.5 to 49.5 weeks of
age. Vector injection in the MBH was performed on week 36.2 (except
in the intact animals), and the number of regular, irregular, and CE
cycles per week was calculated for the pretreatment period (wk 34.5-
36.2) and the posttreatment period (wk 36.2-49.5). N was 6 for the
intact group and 13 for both the DsRed and the IGF-I groups. Asterisks
indicate significant (*P , .05) or highly significant (**P , .01)
differences vs respective preinjection control for a 2-tailed t test for
equal SD. Dagger indicates significant difference for a 1-tailed t test for
significantly different SDs. Reg, regular cycling rats; Irreg., irregular
cycling rats; NS, nonsignificant.
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paredwith rAAV-DsRed-injectedor intact animals, on the
average regularity of the E cycle patterns assessed during
13.3-week postvector injection (Supplemental Figure 2).
As expected, stereotaxic surgery induced a slight loss in
bodyweight that lasted for around 10 days in bothDsRed
and IGF-I rats. Subsequently, animals in the 3 groups
gained weight at the same rate.
In quantitative terms, the average number of regular
cycles perweek before and after IGF-I vector injectionwas
not significantly different. In contrast, intact rats or those
receiving the DsRed control vector showed significantly
lower numbers of regular cycles per week during the post-
treatment period as compared with the pretreatment pe-
riod (Figure 1). The frequency of irregular cycles in the 3
groups was comparable before and after treatment,
whereas thenumberofCEcycles perweek in the intact and
DsRed, but not in the IGF-I animals,
was significantly higher after than
before treatment (Figure 1).
Effect of long-term IGF-I gene
therapy on ovarian histology in
M-A rats
At the end of the study, when rats
were aged 49.5 weeks, animals were
killed and gonads histologically as-
sessed. The ovaries of intact and
DsRed M-A rats weighed signifi-
cantly (P , .01) less than those of
intact young (3mo) counterparts. In-
terestingly, the weight of the ovaries
from IGF-I-treated animals did not
differ significantly from those of in-
tact young rats (data not shown).
The ovaries of both intact and
DsRed,M-A females showed, on the
average, clear structural alterations,
the most conspicuous of which was
the presence of large follicular cysts
(Figure 2, upper and middle images,
respectively), although the extent of
these alterations varied substantially
among animals evenwithin the same
group. In the females from the IGF-I
group, the ovaries had, on the aver-
age, substantially milder structural
alterations, and most of them
showed follicles in all developmental
stages as well as normal CL (Figure
2, bottom image).Histomorphomet-
ric analysis revealed a significantly
lower incidence of follicular cysts in
theovariesof the IGF-I group (Figure
2A). The number of CL was significantly lower in the
intact andDsRed groups than in the IGF-I animals (Figure
2B), whereas the number of atretic, growing, and mature
follicles was not significantly different among groups
(data not shown). The histologic grade, an index of the
structural integrity of the ovaries, was significantly higher
in the IGF-I group than in the intact and DsRed rats (Fig-
ure 2C). The rats with histologic grade 3 had a signifi-
cantly better preserved regularity of E cycles than the an-
imals with histologic grade 1 (data not shown).
Effect of MBH IGF-I gene therapy on serum
hormone levels in M-A rats
Pituitary weight was comparable in the 3 experimental
groups at 49 weeks of age (data not shown). Hormones
Figure 2. (Right panels) Histology of representative ovaries from control and experimental 49.5-
week-old M-A rats submitted to long-term IGF-I gene therapy in the MBH. (Upper panel) Ovarian
section from an intact animal. It was assigned grade 1 and shows large ovarian cysts (OC) but no
CL or mature follicles (MF). (Middle panel) Ovarian section from a DsRed rat. It was assigned
grade 2 and shows numerous atretic follicles (AF) but no CL or MF. Apoptotic cells can be
observed in the follicular space (arrow). Interstitial connective tissue is abundant and highly
cellular. (Bottom panel) Ovarian section from an animal submitted to IGF-I gene therapy. It was
assigned grade 3 and shows developing follicles (DF) and CL of normal aspect as well as some
AF. Scale bar, 300 mm; OM, ovarian medulla. (Left panels) Histomorphometric assessment of the
ovaries of control and rAAV-IGF I-treated MA rats. The number of follicular cysts (A), and CL (B)
per section, and the histologic grade (C) was assessed in the intact (n 5 6), DsRed (n 5 13), and
IGF-I (n 5 13) groups. Asterisks refer to differences vs the IGF-I group (ANOVA followed by the
Tukey’s test); **P , .01 and *P , .05.
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were measured before treatment (wk 35–36) and at the
end of the study (wk 48–49). Serum PRL increased sig-
nificantly in the posttreatment period only in the intact
and DsRed groups. The IGF-I group showed a trend to-
wards an increase, but it did not attain significance (Figure
3, middle panel). Serum LH increased with age and after
vector injection, but this changewas significant only in the
DsRed and IGF-I groups (Figure 3, bottom panel). Serum
E2was affected neither by age nor by the treatment (Figure
3, upper panel). Serum P4 levels were measured at the end
of the study only, and no significant differences were de-
tected among the 3 experimental groups (data not shown).
Discussion
Although the sequence of changes that take place during
reproductive aging in female rats is qualitatively similar in
most strains, the timing is likely to differ among strains
and in different laboratory environments. This is why we
considered it necessary to characterize the chronology of
reproductive changes in our female rat colony before at-
tempting to implement long-term protective gene therapy
in cycling M-A animals. In qualitative terms, the age
changes in vaginal cytology observed in our Sprague-
Dawley females are in agreement with early reports in
Long-Evans rats. Thus, in Long-Evans females, the vagi-
nal smears show regular 4- to 5-day cycles from 2 to 10
months of age, transitioning to irregular cycles and per-
sistent vaginal cornification (CE)during thenext2months
(40, 41). In our M-A females, this transition takes place
earlier. Based on the above results, we started hypotha-
lamic IGF-I gene therapy at 36.2 weeks of age, when a
significant proportion of our rats was still cycling regu-
larly. The bicistronic vector used allowed us to visually
monitor transgene expression in the hypothalamus at dif-
ferent times after virus injection.
The average number of regular and CE cycles per week
was taken as an index of reproductive capacity, the former
being high in rats with regular ovulatory activity and the
latter being high in anovulatory rats (42). The numerous
medium and large ovarian follicular cysts and scarce CL
shown by the intact and DsRed rats at the end of the study
constitute amorphology consistentwith the sustained secre-
tion of FSH, estradiol, and estrone and the low P4 serum
concentrations known to exist in anovulatoryM-A rats (41,
43–45). In contrast, the rats submitted to IGF-I gene therapy
showed substantially better preserved ovaries.
Taken together, the well-preserved histologic features
generally observed in the ovaries from the rats submitted to
IGF-I gene therapy and the vaginal cytology data from the
same animals strongly suggest that the above intervention
delayed the onset of anovulation inM-A females. Addition-
ally, the hormone data indicate that the treatment increased
serum LH levels and attenuated the progressive hyperpro-
lactinemia that develops during aging in female rats (46).
We conclude that long-term overexpression of IGF-I in
the MBH of female rats, started before they transition to
the CE stage, prolongs normal hypothalamo-ovarian
function. Although the mechanism by which this was
achieved remains unknown, some of the studies reviewed
above point to IGF-I as a permissive factor necessary for
Figure 3. Serum hormone levels in M-A rats before and after IGF-I
gene therapy. Blood samples were collected from the tail veins at the
beginning (wk 35–36, pretreatment) and at the end (wk 48–49,
posttreatment) of the study. Numbers in parentheses above columns
indicate the number of samples assessed. Column height and bar
above represents mean and SEM, respectively of each data point.
*P , .05 and **P , .01 vs respective pretreatment value.
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a proper functioning of the positive feedback of E2 on
GnRH release fromGnRHergic terminals into themedian
eminence portal system. This idea is consistent with the
firm evidence that IGF-I and estrogens act synergistically
in the brain both on reproductive function and in neuro-
protection. In fact, an extensive colocalization has been
documented for estrogen and IGF-I receptors both in neu-
rons and astrocytes (47, 48). This colocalization suggests
a cooperative cross talk between the 2 receptors (49).
Because IGF-I content is reduced in the hypothalamus
of M-A rats (17), it could be hypothesized that by pre-
venting the reduction of IGF-I levels in the MBH of our
M-A rats, we preserved the positive feedback of E2 on
GnRH release. This in turnmay not only havemaintained
normal ovulatory cycles, but itmay also have prevented or
at least delayed the progressive disruption that typically
occurs in ovarian steroid secretion in M-A rats (45, 50).
The progressive delay and amplitude reduction in P LH
surges (and the increased FSH secretion) in M-A female
rats are thought to lead to persistently sustained ovarian
E2 secretion, which over time exerts an inhibitory action
on the steroid positive feedback mechanism on hypotha-
lamic GnRH release (51, 52), thus further inhibiting the
preovulatory LH surge. In any case, IGF-I is probably one
of many permissive molecules contributing to a proper
functioningof the positive steroid feedbackmechanismon
GnRH.Thus, hypothalamic IGF-I overexpressionby itself
should not be expected to indefinitely prolong regular cy-
clicity in M-A rats. As time passes, the hypothalamic ex-
pression of other permissive factors may also drop below
critical levels, and the positive steroid feedback mecha-
nism on GnRH driving preovulatory LH surges will even-
tually fail even in rats undergoing hpothalamic IGF-I gene
therapy. Because the pituitary gland and the ovaries of old
female rats transplanted into young hypophysectomized/
ovariectomized recipients can sustain vaginal cyclicity
(53), it appears that the hypothalamus is the critically age-
sensitive component of the hypothalamo-pituitary-ovar-
ian axis in rats. Therefore, the implementation of hypo-
thalamic multigene therapy for an appropriate set of
permissive factors may allow extending normal ovarian
function of M-A female rats well into old age.
Inrats, reproductivesenescenceoccurs inmidlife,whereas
in some nonhuman primates, such as rhesus monkeys, this
process occurs much later in life (54). Despite this and other
interspeciesdifferences in reproductiveaging,understanding
the basic mechanisms that trigger age changes in the rodent
reproductive hypothalamus is likely to shed light on hypo-
thalamic aging in primates, including humans.
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